TickerTalks
Browse all tickers →
TickerTalks›$NKTR
NKNKTR

Nektar Therapeutics

$NKTR·$1.6B·Biotechnology·Healthcare
$59.24-1.9%YTD+39.4%1Y+0.5%
Price updated 13h ago·X counts updated 2d ago
NKNKTR
$NKTRNektar Therapeutics
$59.24-1.92%637 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $NKTR on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

637X posts · last 7 days
Sep 12Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $NKTR's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bearish sentimentAI analysisGenerated by AI from underlying data9 posts analyzed · as of 2026-09-29

Nektar holders are dejected, mourning the LLY lawsuit ruling that awarded only $90M for breach of the implied covenant of good faith (no express-contract breach found). The stock is down 48% from the high while in a "quiet period," and the mood is captured by "deathtouch" and "final results — NKTR going to zero next" jokes; one contrarian argues Two Seas Capital may have been buying into the selling pressure.

Read what X is saying about $NKTR

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NKTR — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventCooling offAI verdict · as of 2026-09-30

Catching its breath after a run — could pick back up or fade from here.

Nektar took a $90M consolation from Lilly and the market read it as a loss — everything now rides on rezpegaldesleukin data.

Nektar Therapeutics is a clinical-stage biotech whose lead asset is now rezpegaldesleukin (formerly Bempegaldesleukin) — an IL-2 pathway agonist being repositioned in dermatology (atopic dermatitis, alopecia) after the oncology program with Bristol-Myers failed.

  • The Lilly lawsuit landed short of hopes: the court awarded $90M on breach of the implied covenant only — no express-contract breach, meaning bulls calling for a much larger payout got the smaller version and the stock is down 48% from the high.
  • The pipeline still has real optionality: three oral presentations of rezpeg data at EADV Congress 2026 are coming, and analyst-priced-right notes flag two make-or-break catalysts near-term — this remains a data-readout stock, for better and worse.
  • The financial base is thin: revenue is a rounding error ($11M last quarter), operating margin is -225%, and the last twelve months of EPS are deeply negative — this is not a self-funding business, it's a bet on the data.

Cooling (below the 50-day, 34% of the 52w range) with the Nov 5 print and the EADV Congress rezpeg data as the near-term catalysts. Positive dermatology data breaks the drift; another disappointing readout in the sequence and the tape resolves lower toward the 'going to zero' bear extreme.

Agrees with X sentimentThe chatter is capturing the exact right tension — the $90M Lilly award being smaller than the express-contract case bulls had hoped, and the 'quiet period' mood into the EADV data — with the contrarian note about Two Seas potentially accumulating being the honest upside offset. The 'going to zero' extreme reads as gallows humor, not thesis.

What to watch: The three EADV Congress 2026 rezpeg oral presentations and Q3 earnings Nov 5 — positive dermatology data breaks the drift; another disappointing readout resolves the tape lower. Watch Two Seas Capital and other special-situations funds for accumulation signals.

On the calendar: 2026-11-05 — Q3 earnings

Read the AI verdict on $NKTR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Biopharma developing bempegaldesleukin, a CD122-preferential IL-2 pathway agonist, for melanoma, renal cell carcinoma, and other immuno-oncology indications.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NKTR.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $NKTR

Partial — Biopharma developing bempegaldesleukin, a CD122-preferential IL-2 pathway agonist, for melanoma, renal cell carcinoma, and other immuno-oncology indications.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.4%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-17.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-225%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-16.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
21.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-87.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-1.23$-1.97+37.6%
Q1 2026May 7, 2026$-1.82$-1.58-15.0%
Q4 2025Mar 12, 2026$-1.78$-2.47+28.1%
Q3 2025Nov 6, 2025$-1.85$-2.85+35.1%
Next earningsThu, Nov 5·consensus EPS $-2.17

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$10.9M+3.8%98.6%-352%$-1.82$-44.3M
Q4 FY25$21.8M-25.3%100%-87.5%$-1.78$-65.0M
Q3 FY25$11.8M-51.1%98.3%-267%$-1.87$-48.9M
Q2 FY25$11.2M-52.4%100%-324%$-2.95$-45.8M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$41.9M$41.3M – $43.2M-$8.09-$9.41 – -$6.9310
FY27$57.0M$16.2M – $240.1M-$10.25-$18.06 – -$3.7010
FY28$38.6M$36.9M – $40.3M-$10.64-$19.84 – -$6.4111
FY29$51.3M$26.4M – $167.2M-$8.76-$34.47 – -$3.235
FY30$175.9M$90.5M – $573.5M-$5.23-$20.60 – -$1.935

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.34%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-9.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 29.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.155-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 18Jonathan ZalevskyChief R&D Officer186 sh$13KSellAug 18Howard W RobinCEO418 sh$30KSellJun 30Jonathan ZalevskyChief R&D Officer5.7K sh$398KSellJun 17Howard W RobinCEO10.0K sh$612KSellJun 16Howard W RobinCEO10.0K sh$603KSellJun 15Jonathan ZalevskyChief R&D Officer5.5K sh$336KSellMay 19Howard W RobinCEO444 sh$29KSellMay 19Jonathan ZalevskyChief R&D Officer199 sh$13K
+ 7 other (7 awards) in window

See when $NKTR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 88-K — Item 7.01: Press release / Reg FD
AI summary

Nektar Therapeutics announced on September 8, 2026, that it is implementing a quiet period while awaiting 24-week follow-up data from the Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata patients. The quiet period follows the company's established practice around planned data disclosures from the REZOLVE study program. The information is furnished under Item 7.01 (Reg FD) and is not filed for Exchange Act Section 18 purposes.

8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
AI summary

Nektar Therapeutics (NKTR) reported its June 4, 2026 Annual Meeting results. Howard W. Robin was elected to the board (Class III, until 2029) with 13,164,879 votes for vs. 4,975,288 against — a notable 27% dissent rate. The 2017 Performance Incentive Plan was amended to add 3,000,000 shares authorized for issuance (approved 13.16M for / 4.90M against). Ernst & Young LLP was ratified as auditor. The ~27% against vote for the sole director election is a governance flag; the 3M additional share authorization is modestly dilutive for a small-cap biotech.

3New insider — initial holdingsMay 263
AI summary

Linda M. Rubinstein filed a Form 3 as Interim CFO of Nektar Therapeutics (NKTR) on May 26, 2026, triggered by her appointment on May 15, 2026. Rubinstein is based at Nektar's San Francisco headquarters. The filing discloses no securities beneficially owned. Routine Form 3 for a newly appointed interim CFO — the 'interim' designation signals an ongoing CFO search at this clinical-stage biotech.

424B5Prospectus supplement (offering)May 8424B5
AI summary

Nektar Therapeutics (NKTR) filed a 424B5 prospectus supplement on May 8, 2026 for an ATM offering of up to $150M in common stock via Guggenheim Securities and H.C. Wainwright as sales agents (3.0% commission). The last reported sale price was $85.09 on May 6, 2026. No shares had been sold as of filing. The $150M ATM program is a meaningful potential dilution for a clinical-stage biotech, indicating management is building flexible capital reserves ahead of upcoming clinical milestones.

8-KMaterial agreementMay 88-K — Item 1.01: Material agreement · Item 5.02: Officer or director change
AI summary

Nektar Therapeutics (NKTR) entered an Equity Distribution Agreement on May 8, 2026 with Guggenheim Securities and H.C. Wainwright for an ATM offering of up to $150M in common stock (3.0% commission), registered under Nektar's November 2025 S-3 shelf. No obligation to sell; the program provides an on-demand capital raising mechanism through Nasdaq. A material liquidity option for a biotech dependent on external funding, complementing the concurrent 424B5 filing.

8-KMaterial agreementApr 238-K — Item 1.01: Material agreement · Item 8.01: Other event
424B5Prospectus supplement (offering)Apr 23424B5
424B5Prospectus supplement (offering)Apr 20424B5
+ 19 other (8 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026prnewswire.com·2d agoNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com·5d agoAnalyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX)defenseworld.net·13d agoHB Wealth Management LLC Purchases New Position in Nektar Therapeutics $NKTRdefenseworld.net·16d agoNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com·33d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$ABVX
Voices on X · top 9 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport